Supporting transformational treatments for rare disorders

A Rare Disease Day retrospective

Maintaining business continuity during COVID-19

Lessons learned will have positive impacts beyond the pandemic

Scaling cell therapy supply chains during a pandemic

Achieving donor pool sustainability and cell therapy supply chain success

Being an NMDP/Be The Match courier during COVID-19

Making essential treatments possible in the midst of a pandemic

5 Qualities to Seek in Your Cell Therapy Supply Chain Vendor

Considerations to help lower your cell or gene therapy logistics risk

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter